PE20121010A1 - Derivados de bencimidazol - Google Patents

Derivados de bencimidazol

Info

Publication number
PE20121010A1
PE20121010A1 PE2012000473A PE2012000473A PE20121010A1 PE 20121010 A1 PE20121010 A1 PE 20121010A1 PE 2012000473 A PE2012000473 A PE 2012000473A PE 2012000473 A PE2012000473 A PE 2012000473A PE 20121010 A1 PE20121010 A1 PE 20121010A1
Authority
PE
Peru
Prior art keywords
methylpiperidin
alkyl
benzimidazole
compounds
halo
Prior art date
Application number
PE2012000473A
Other languages
English (en)
Inventor
Christopher Scott Jones
Michael John Munchhof
Lawrence Alan Reiter
Susan La Greca
Qifang Li
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20121010A1 publication Critical patent/PE20121010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (IIa) DONDE R1 ES HALO, ALQUILO(C1-C6), ALCOXI(C1-C6), -CF3, ENTRE OTROS; R2 ES H; R3B ES H, ALQUILO(C1-C6), -(CH2)t(C6-C12) O -(CH2)t(C3-C12)CARBOCICLILO, EN DONDE t ES DE 0 A 2; R4 ES H; R10 ES -(CH2)t(C6-C12)ARILO O -(CH2)t(HETEROCICLILO DE 4 A 14 MIEMBROS) OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C6), CN, HALO, OCF3, ENTRE OTROS; n ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(4-CIANOFENIL)UREA; N-[(2R,4R)-2-(6-CLORO-1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-2,3-DIHIDRO-1,4-BENZODIOXINA-6-CARBOXAMIDA; 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(4-METOXIFENIL)UREA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CRECIMIENTO CELULAR ANORMAL TAL COMO CANCER
PE2012000473A 2007-06-29 2008-06-27 Derivados de bencimidazol PE20121010A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02

Publications (1)

Publication Number Publication Date
PE20121010A1 true PE20121010A1 (es) 2012-08-06

Family

ID=40161351

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001105A PE20090772A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol
PE2012000473A PE20121010A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008001105A PE20090772A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol

Country Status (46)

Country Link
US (2) US8148401B2 (es)
EP (1) EP2170860B9 (es)
JP (2) JP4567099B2 (es)
KR (1) KR101143246B1 (es)
CN (1) CN101687841B (es)
AP (1) AP2377A (es)
AR (1) AR067346A1 (es)
AU (1) AU2008272641B2 (es)
BR (1) BRPI0813412B8 (es)
CA (1) CA2690953C (es)
CL (1) CL2008001922A1 (es)
CO (1) CO6160232A2 (es)
CR (1) CR11150A (es)
CU (1) CU23847B1 (es)
CY (2) CY1118650T1 (es)
DK (1) DK2170860T5 (es)
DO (1) DOP2009000278A (es)
EA (1) EA016888B1 (es)
EC (1) ECSP099803A (es)
ES (1) ES2609258T3 (es)
FR (1) FR20C1038I2 (es)
GE (1) GEP20125702B (es)
GT (1) GT200900328A (es)
HK (1) HK1139658A1 (es)
HN (1) HN2008000974A (es)
HR (1) HRP20161562T2 (es)
HU (2) HUE030052T4 (es)
IL (1) IL202420A (es)
LT (2) LT2170860T (es)
MA (1) MA31466B1 (es)
ME (1) ME00962B (es)
MY (1) MY148636A (es)
NI (1) NI200900219A (es)
NL (1) NL301057I2 (es)
NO (1) NO2020027I1 (es)
NZ (1) NZ581889A (es)
PA (1) PA8785401A1 (es)
PE (2) PE20090772A1 (es)
PL (1) PL2170860T3 (es)
PT (1) PT2170860T (es)
RS (1) RS55395B9 (es)
SI (1) SI2170860T1 (es)
TN (1) TN2009000544A1 (es)
TW (1) TWI371451B (es)
UY (1) UY31164A1 (es)
WO (1) WO2009004427A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2170860T1 (sl) 2007-06-29 2017-01-31 Pfizer Inc. Benzimidazolni derivati
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
RU2533825C2 (ru) * 2009-06-11 2014-11-20 Сиена Байотек С.П.А. ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА И ИМИДАЗО[4,5-с]ПИРИДИНА, В КАЧЕСТВЕ АНТАГОНИСТА ПУТИ HEDGEHOG
EA201270311A1 (ru) 2009-08-26 2012-09-28 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое производное и его применение
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA3061239A1 (en) 2011-02-28 2012-09-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2684167B1 (en) * 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
ES2612934T3 (es) 2011-09-26 2017-05-19 Merck Patent Gmbh Compuestos de piperidin bencilo como antagonista del receptor del ácido lisofosfatídico (LPA)
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
ES2680224T3 (es) 2013-03-15 2018-09-05 Biomarin Pharmaceutical Inc. Inhibidores de HDAC
WO2014170350A1 (en) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
MX2017013645A (es) 2015-04-24 2018-03-08 Pfizer Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-me tilpiperidin-4-il)-3-(4-cianofenil)urea maleato.
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
US20230107634A1 (en) 2020-01-28 2023-04-06 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
TW202216133A (zh) 2020-06-26 2022-05-01 日商拉夸里亞創藥股份有限公司 類視色素與癌症治療藥之併用療法有效之癌症患者之選擇方法及類視色素與癌症治療藥之併用醫藥
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002327390B2 (en) 2001-07-27 2008-06-26 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1499607B1 (en) * 2001-12-04 2005-12-07 Actelion Pharmaceuticals Ltd. 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004035549A1 (en) 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
CN1902181A (zh) 2003-10-28 2007-01-24 沃泰克斯药物股份有限公司 可用作离子通道调控剂的苯并咪唑
US7816369B2 (en) * 2004-11-03 2010-10-19 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
SI2170860T1 (sl) 2007-06-29 2017-01-31 Pfizer Inc. Benzimidazolni derivati
WO2009154739A2 (en) 2008-06-17 2009-12-23 Duke University Smoothened receptor modulators
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors

Also Published As

Publication number Publication date
CY1118650T1 (el) 2017-07-12
ES2609258T3 (es) 2017-04-19
EP2170860B1 (en) 2016-11-02
CY2020028I1 (el) 2020-11-25
CO6160232A2 (es) 2010-05-20
EA016888B1 (ru) 2012-08-30
HRP20161562T2 (hr) 2017-04-21
HN2008000974A (es) 2011-01-24
AP2377A (en) 2012-03-07
PT2170860T (pt) 2017-01-04
IL202420A (en) 2014-05-28
HUE030052T2 (hu) 2017-04-28
GT200900328A (es) 2011-08-29
CU20090225A7 (es) 2012-02-15
EA200971104A1 (ru) 2010-06-30
CA2690953C (en) 2012-10-02
DOP2009000278A (es) 2009-12-31
CR11150A (es) 2010-02-08
SI2170860T1 (sl) 2017-01-31
AP2009005089A0 (en) 2009-12-31
AU2008272641A1 (en) 2009-01-08
IL202420A0 (en) 2010-06-30
AU2008272641B2 (en) 2013-08-29
RS55395B9 (sr) 2020-01-31
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
US8431597B2 (en) 2013-04-30
EP2170860A2 (en) 2010-04-07
GEP20125702B (en) 2012-12-10
LTPA2020528I1 (lt) 2020-09-25
TN2009000544A1 (fr) 2011-03-31
CL2008001922A1 (es) 2009-01-02
AR067346A1 (es) 2009-10-07
KR20100028120A (ko) 2010-03-11
HUE030052T4 (en) 2017-06-28
BRPI0813412A2 (pt) 2014-12-30
ME00962B (me) 2012-06-20
MA31466B1 (fr) 2010-06-01
MY148636A (en) 2013-05-15
WO2009004427A2 (en) 2009-01-08
CN101687841A (zh) 2010-03-31
US20090005416A1 (en) 2009-01-01
NO2020027I1 (no) 2020-08-11
TWI371451B (en) 2012-09-01
JP2010280693A (ja) 2010-12-16
US20120157495A1 (en) 2012-06-21
HRP20161562T1 (hr) 2016-12-30
LTC2170860I2 (lt) 2022-03-10
PA8785401A1 (es) 2009-01-23
UY31164A1 (es) 2009-01-30
BRPI0813412B8 (pt) 2021-05-25
NL301057I2 (nl) 2020-09-10
DK2170860T5 (en) 2017-03-20
WO2009004427A3 (en) 2009-06-04
NZ581889A (en) 2011-05-27
PL2170860T3 (pl) 2017-05-31
KR101143246B1 (ko) 2012-05-18
CA2690953A1 (en) 2009-01-08
DK2170860T3 (en) 2017-01-09
TW200911792A (en) 2009-03-16
FR20C1038I1 (es) 2020-10-02
BRPI0813412B1 (pt) 2020-01-21
CU23847B1 (es) 2012-10-15
JP2010531869A (ja) 2010-09-30
NL301057I1 (nl) 2020-07-22
HK1139658A1 (en) 2010-09-24
ECSP099803A (es) 2010-01-29
CN101687841B (zh) 2013-07-10
FR20C1038I2 (fr) 2021-08-13
US8148401B2 (en) 2012-04-03
HUS2000031I1 (hu) 2020-09-28
RS55395B1 (sr) 2017-04-28
LT2170860T (lt) 2017-01-10
JP4567099B2 (ja) 2010-10-20
EP2170860B9 (en) 2017-02-22
CY2020028I2 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
PE20121010A1 (es) Derivados de bencimidazol
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20140690A1 (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20130647A1 (es) Indoles
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
PE20060977A1 (es) Derivados de piperidinilo como bloqueantes de canales de calcio
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20061316A1 (es) Derivados de pirazol como antagonistas del receptor de progesterona
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen

Legal Events

Date Code Title Description
FG Grant, registration